Solvonis Therapeutics (LON: SVNS) shares surged 13% in early trading after the company announced positive preclinical pharmacokinetic data for its lead Alcohol Use Disorder treatment candidate, SVN-002, marking an important
Avacta Extends Cash Runway as Clinical Pipeline Advances
Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of
Genflow Biosciences to Showcase Longevity Gene Therapy Data at Major Industry Summit
Genflow Biosciences plc (LON: GENF) has been invited to present results from its SLAB (Sarcopenia and Longevity in Aged Beagles) study at the Animal Longevity Summit 2026, a specialist conference
Poolbeg Pharma (AIM: POLB) European patent granted for POLB 001 in CRS
Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS Major milestone will provide IP protection in key European markets, strengthening global patent portfolio
MedPal AI Shares Jump 40% as UK Approves First Oral GLP-1 Weight Loss Treatment
Shares in MedPal AI plc (AIM: MPAL) surged 40% during Friday trading to a three-month high of around 4.35p after the company highlighted the UK approval of the first oral
Poolbeg Pharma PLC (AIM: POLB) Preclinical data posters presented at EHA Congress
Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
£9m fundraising gives Avacta extra firepower for cancer pipeline
Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting
OptiBiotix Health plc Investor presentation and SweetBiotix® Sampling
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes
Avacta showcases progress in salivary gland cancer study
Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially
Why Physiomics Could Be Entering A New Phase Of Commercial Growth
Physiomics plc (AIM: PYC) is one of those AIM microcaps that can easily be overlooked at first glance. The company operates in a specialist corner of the healthcare sector, providing
Avacta Therapeutics (AIM: AVCT) Board Director Changes
Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.
CelLBxHealth rises 33% after signing AstraZeneca deal
CelLBxHealth plc (AIM: CLBX) surged 33% in early trading after announcing a Master Services Agreement with pharmaceutical giant AstraZeneca.